Neuromyelitis Optica Spectrum Disorder
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica Spectrum Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder [NA]
Clinical trial update on MR-C-014 for neuromyelitis optica spectrum disorder, focusing on acceptability and safety, with enrollment by invit…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 4]
This update describes a Phase 4, long-term, open-label safety study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) that i…
-
CLINICAL_TRIALS trial_result · 2025-06-23Clinical Trial Update: Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
This completed clinical trial assessed the efficacy and safety of conventional immunosuppressant therapies in elderly patients with neuromye…
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder [Phase 1, Phase 2]
A clinical trial registry update describes the phase 1/2 evaluation of BAFFR CAR T cells for relapsed or refractory Neuromyelitis Optica Spe…
-
CLINICAL_TRIALS trial_result · 2025-04-30Clinical Trial Update: High Frequency Impulse Therapy for Neuropathic Pain in NMOSD [Phase 2]
The update reports the completion of a Phase 2 trial evaluating High Frequency Impulse Therapy for neuropathic pain in Neuromyelitis Optica …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]
Clinical trial update notes safety and efficacy evaluation of daratumumab in patients with anti-AQP4 antibody positive neuromyelitis optica …
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention [Phase 4]
Clinical trial update reporting results from a Phase 4 study of satralizumab in neuromyelitis optica spectrum disorder, with the trial termi…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: ACT with NMOSD Patients and Caregivers Pilot Study [NA]
A completed pilot clinical trial evaluating ACT with Neuromyelitis Optica Spectrum Disorder patients and caregivers; sponsored by Thomas Jef…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
Phase 3 trial evaluating the safety and efficacy of satralizumab in Neuromyelitis Optica Spectrum Disorder has completed and results have be…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD [Phase 1]
A Phase 1 clinical trial sponsored by Bioray Laboratories is evaluating universal BCMA-targeting CAR-T cells for refractory neuromyelitis op…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders [Phase 1, Phase 2]
This clinical trial update reports Phase 1/2 data on the efficacy and safety of belimumab in neuromyelitis optica spectrum disorder. The stu…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2, Phase 3]
A pediatric Phase 2/3 trial of eculizumab for relapsing neuromyelitis optica spectrum disorder was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 2]
A Phase 2 clinical trial evaluating mitoxantrone hydrochloride liposome injection for Neuromyelitis Optica Spectrum Disorder has completed, …
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder [Phase 2]
Phase 2 trial evaluating bortezomib as add-on therapy for relapsing neuromyelitis optica spectrum disorder completed.
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD [Phase 3]
Phase 3 trial of ravulizumab in adults with neuromyelitis optica spectrum disorder has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-23Clinical Trial Update: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients [Phase 3]
Open-label extension of eculizumab in relapsing neuromyelitis optica shows continuing assessment in a Phase 3 study.
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
A Phase 3 trial evaluated satralizumab as monotherapy for neuromyelitis optica and NMOSD, with completed status and results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) [Phase 4]
Phase 4 trial update evaluating low-dose rituximab for neuromyelitis optica spectrum disorder has been completed.
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients [Phase 2, Phase 3]
A completed Phase 2/3 trial comparing azathioprine and rituximab in neuromyelitis optica spectrum disorder.
-
CLINICAL_TRIALS trial_result · 2019-08-22Clinical Trial Update: Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders [Phase 2]
Phase 2 clinical trial comparing immunoadsorption versus plasma exchange for acute attacks in refractory neuromyelitis optica spectrum disor…
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) [Phase 3]
Phase 3 randomized trial of eculizumab in AQP4 antibody-positive neuromyelitis optica spectrum disorder was terminated; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-06-06Clinical Trial Update: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses [Phase 1]
Phase 1 trial update evaluating ublituximab for relapses in neuromyelitis optica and related spectrum disorders; results posted after comple…
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Central Pain Study for ABX-1431 [Phase 1]
Phase 1 central pain study of ABX-1431 conducted by Abide Therapeutics has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. [Phase 2]
Phase II trial of NPB-01 in anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder has completed; the document’s wording …
-
CLINICAL_TRIALS trial_result · 2016-06-22Clinical Trial Update: Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients [Phase 4]
Phase 4 clinical trial assessing the efficacy and safety of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum dis…